342 related articles for article (PubMed ID: 32326087)
1. Recent Synthetic Approaches towards Small Molecule Reactivators of p53.
Silva JL; Lima CGS; Rangel LP; Ferretti GDS; Pauli FP; Ribeiro RCB; da Silva TB; da Silva FC; Ferreira VF
Biomolecules; 2020 Apr; 10(4):. PubMed ID: 32326087
[TBL] [Abstract][Full Text] [Related]
2. Awakening the "guardian of genome": reactivation of mutant p53.
Binayke A; Mishra S; Suman P; Das S; Chander H
Cancer Chemother Pharmacol; 2019 Jan; 83(1):1-15. PubMed ID: 30324219
[TBL] [Abstract][Full Text] [Related]
3. Mutant p53 reactivation by small molecules makes its way to the clinic.
Bykov VJ; Wiman KG
FEBS Lett; 2014 Aug; 588(16):2622-7. PubMed ID: 24768524
[TBL] [Abstract][Full Text] [Related]
4. Wild type p53 reactivation: from lab bench to clinic.
Selivanova G
FEBS Lett; 2014 Aug; 588(16):2628-38. PubMed ID: 24726725
[TBL] [Abstract][Full Text] [Related]
5. Recent Small-Molecule Inhibitors of the p53-MDM2 Protein-Protein Interaction.
Beloglazkina A; Zyk N; Majouga A; Beloglazkina E
Molecules; 2020 Mar; 25(5):. PubMed ID: 32156064
[TBL] [Abstract][Full Text] [Related]
6. Small molecule agents targeting the p53-MDM2 pathway for cancer therapy.
Wang W; Hu Y
Med Res Rev; 2012 Nov; 32(6):1159-96. PubMed ID: 23059763
[TBL] [Abstract][Full Text] [Related]
7. Small-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory Axis.
Hiraki M; Hwang SY; Cao S; Ramadhar TR; Byun S; Yoon KW; Lee JH; Chu K; Gurkar AU; Kolev V; Zhang J; Namba T; Murphy ME; Newman DJ; Mandinova A; Clardy J; Lee SW
Chem Biol; 2015 Sep; 22(9):1206-16. PubMed ID: 26320861
[TBL] [Abstract][Full Text] [Related]
8. Small Molecules Targeting Mutant P53: A Promising Approach for Cancer Treatment.
Lopes EA; Gomes S; Saraiva L; Santos MMM
Curr Med Chem; 2019; 26(41):7323-7336. PubMed ID: 30444195
[TBL] [Abstract][Full Text] [Related]
9. Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed.
Zanjirband M; Rahgozar S
Curr Drug Targets; 2019; 20(11):1091-1111. PubMed ID: 30947669
[TBL] [Abstract][Full Text] [Related]
10. Small molecule compounds targeting the p53 pathway: are we finally making progress?
Yu X; Narayanan S; Vazquez A; Carpizo DR
Apoptosis; 2014 Jul; 19(7):1055-68. PubMed ID: 24756955
[TBL] [Abstract][Full Text] [Related]
11. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
Sirous H; Chemi G; Campiani G; Brogi S
Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
[TBL] [Abstract][Full Text] [Related]
12. Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy.
Gupta AK; Bharadwaj M; Kumar A; Mehrotra R
Top Curr Chem (Cham); 2017 Feb; 375(1):3. PubMed ID: 27943171
[TBL] [Abstract][Full Text] [Related]
13. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer.
Patel S; Player MR
Expert Opin Investig Drugs; 2008 Dec; 17(12):1865-82. PubMed ID: 19012502
[TBL] [Abstract][Full Text] [Related]
14. Small molecule activators of the p53 response.
Ladds MJGW; Laín S
J Mol Cell Biol; 2019 Mar; 11(3):245-254. PubMed ID: 30689917
[TBL] [Abstract][Full Text] [Related]
15. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.
Xu-Monette ZY; Medeiros LJ; Li Y; Orlowski RZ; Andreeff M; Bueso-Ramos CE; Greiner TC; McDonnell TJ; Young KH
Blood; 2012 Apr; 119(16):3668-83. PubMed ID: 22275381
[TBL] [Abstract][Full Text] [Related]
16. Reactivation of wild-type and mutant p53 by tryptophanolderived oxazoloisoindolinone SLMP53-1, a novel anticancer small-molecule.
Soares J; Raimundo L; Pereira NA; Monteiro Â; Gomes S; Bessa C; Pereira C; Queiroz G; Bisio A; Fernandes J; Gomes C; Reis F; Gonçalves J; Inga A; Santos MM; Saraiva L
Oncotarget; 2016 Jan; 7(4):4326-43. PubMed ID: 26735173
[TBL] [Abstract][Full Text] [Related]
17. p53 dynamics in response to DNA damage vary across cell lines and are shaped by efficiency of DNA repair and activity of the kinase ATM.
Stewart-Ornstein J; Lahav G
Sci Signal; 2017 Apr; 10(476):. PubMed ID: 28442631
[TBL] [Abstract][Full Text] [Related]
18. A balancing act: using small molecules for therapeutic intervention of the p53 pathway in cancer.
Miller JJ; Gaiddon C; Storr T
Chem Soc Rev; 2020 Oct; 49(19):6995-7014. PubMed ID: 32869798
[TBL] [Abstract][Full Text] [Related]
19. Targeting mutant p53 for efficient cancer therapy.
Bykov VJN; Eriksson SE; Bianchi J; Wiman KG
Nat Rev Cancer; 2018 Feb; 18(2):89-102. PubMed ID: 29242642
[TBL] [Abstract][Full Text] [Related]
20. Reactivation of mutant p53 by capsaicin, the major constituent of peppers.
Garufi A; Pistritto G; Cirone M; D'Orazi G
J Exp Clin Cancer Res; 2016 Sep; 35(1):136. PubMed ID: 27599722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
